These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

518 related articles for article (PubMed ID: 31488222)

  • 1. Impaired dopamine metabolism in Parkinson's disease pathogenesis.
    Masato A; Plotegher N; Boassa D; Bubacco L
    Mol Neurodegener; 2019 Aug; 14(1):35. PubMed ID: 31488222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oligomerization and Membrane-binding Properties of Covalent Adducts Formed by the Interaction of α-Synuclein with the Toxic Dopamine Metabolite 3,4-Dihydroxyphenylacetaldehyde (DOPAL).
    Follmer C; Coelho-Cerqueira E; Yatabe-Franco DY; Araujo GD; Pinheiro AS; Domont GB; Eliezer D
    J Biol Chem; 2015 Nov; 290(46):27660-79. PubMed ID: 26381411
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rotenone decreases intracellular aldehyde dehydrogenase activity: implications for the pathogenesis of Parkinson's disease.
    Goldstein DS; Sullivan P; Cooney A; Jinsmaa Y; Kopin IJ; Sharabi Y
    J Neurochem; 2015 Apr; 133(1):14-25. PubMed ID: 25645689
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DOPAL initiates αSynuclein-dependent impaired proteostasis and degeneration of neuronal projections in Parkinson's disease.
    Masato A; Plotegher N; Terrin F; Sandre M; Faustini G; Thor A; Adams S; Berti G; Cogo S; De Lazzari F; Fontana CM; Martinez PA; Strong R; Bandopadhyay R; Bisaglia M; Bellucci A; Greggio E; Dalla Valle L; Boassa D; Bubacco L
    NPJ Parkinsons Dis; 2023 Mar; 9(1):42. PubMed ID: 36966140
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vesicular uptake blockade generates the toxic dopamine metabolite 3,4-dihydroxyphenylacetaldehyde in PC12 cells: relevance to the pathogenesis of Parkinson's disease.
    Goldstein DS; Sullivan P; Cooney A; Jinsmaa Y; Sullivan R; Gross DJ; Holmes C; Kopin IJ; Sharabi Y
    J Neurochem; 2012 Dec; 123(6):932-43. PubMed ID: 22906103
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aldehyde dehydrogenase inhibition generates a reactive dopamine metabolite autotoxic to dopamine neurons.
    Doorn JA; Florang VR; Schamp JH; Vanle BC
    Parkinsonism Relat Disord; 2014 Jan; 20 Suppl 1(0 1):S73-5. PubMed ID: 24262193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determinants of buildup of the toxic dopamine metabolite DOPAL in Parkinson's disease.
    Goldstein DS; Sullivan P; Holmes C; Miller GW; Alter S; Strong R; Mash DC; Kopin IJ; Sharabi Y
    J Neurochem; 2013 Sep; 126(5):591-603. PubMed ID: 23786406
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequestosome-1 (SQSTM1/p62) as a target in dopamine catabolite-mediated cellular dyshomeostasis.
    Masato A; Andolfo A; Favetta G; Bellini EN; Cogo S; Dalla Valle L; Boassa D; Greggio E; Plotegher N; Bubacco L
    Cell Death Dis; 2024 Jun; 15(6):424. PubMed ID: 38890356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dihydroxyphenylacetaldehyde Lowering Treatment Improves Locomotor and Neurochemical Abnormalities in the Rat Rotenone Model: Relevance to the Catecholaldehyde Hypothesis for the Pathogenesis of Parkinson's Disease.
    Khashab R; Gutman-Sharabi N; Shabtai Z; Landau R; Halperin R; Fay-Karmon T; Leibowitz A; Sharabi Y
    Int J Mol Sci; 2023 Aug; 24(15):. PubMed ID: 37569897
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Catecholaldehyde Hypothesis for the Pathogenesis of Catecholaminergic Neurodegeneration: What We Know and What We Do Not Know.
    Goldstein DS
    Int J Mol Sci; 2021 Jun; 22(11):. PubMed ID: 34206133
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of Monoamine Oxidase Inhibitors in Decreasing Production of the Autotoxic Dopamine Metabolite 3,4-Dihydroxyphenylacetaldehyde in PC12 Cells.
    Goldstein DS; Jinsmaa Y; Sullivan P; Holmes C; Kopin IJ; Sharabi Y
    J Pharmacol Exp Ther; 2016 Feb; 356(2):483-92. PubMed ID: 26574516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inactivation of glyceraldehyde-3-phosphate dehydrogenase by the dopamine metabolite, 3,4-dihydroxyphenylacetaldehyde.
    Vanle BC; Florang VR; Murry DJ; Aguirre AL; Doorn JA
    Biochem Biophys Res Commun; 2017 Oct; 492(2):275-281. PubMed ID: 28830811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protein reactivity of 3,4-dihydroxyphenylacetaldehyde, a toxic dopamine metabolite, is dependent on both the aldehyde and the catechol.
    Rees JN; Florang VR; Eckert LL; Doorn JA
    Chem Res Toxicol; 2009 Jul; 22(7):1256-63. PubMed ID: 19537779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of Parkinson's Disease-Linked Mutations and N-Terminal Acetylation on the Oligomerization of α-Synuclein Induced by 3,4-Dihydroxyphenylacetaldehyde.
    Lima VA; do Nascimento LA; Eliezer D; Follmer C
    ACS Chem Neurosci; 2019 Jan; 10(1):690-703. PubMed ID: 30352158
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Catechol and aldehyde moieties of 3,4-dihydroxyphenylacetaldehyde contribute to tyrosine hydroxylase inhibition and neurotoxicity.
    Vermeer LM; Florang VR; Doorn JA
    Brain Res; 2012 Sep; 1474():100-9. PubMed ID: 22877852
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro inhibition of glutathione-S-transferase by dopamine and its metabolites, 3,4-dihydroxyphenylacetaldehyde and 3,4-dihydroxyphenylacetic acid.
    Crawford RA; Bowman KR; Cagle BS; Doorn JA
    Neurotoxicology; 2021 Sep; 86():85-93. PubMed ID: 34314733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 3,4-Dihydroxyphenylacetaldehyde potentiates the toxic effects of metabolic stress in PC12 cells.
    Lamensdorf I; Eisenhofer G; Harvey-White J; Nechustan A; Kirk K; Kopin IJ
    Brain Res; 2000 Jun; 868(2):191-201. PubMed ID: 10854571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dopamine-derived biological reactive intermediates and protein modifications: Implications for Parkinson's disease.
    Jinsmaa Y; Florang VR; Rees JN; Mexas LM; Eckert LL; Allen EM; Anderson DG; Doorn JA
    Chem Biol Interact; 2011 Jun; 192(1-2):118-21. PubMed ID: 21238438
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of the oxidative metabolism of 3,4-dihydroxyphenylacetaldehyde, a reactive intermediate of dopamine metabolism, by 4-hydroxy-2-nonenal.
    Florang VR; Rees JN; Brogden NK; Anderson DG; Hurley TD; Doorn JA
    Neurotoxicology; 2007 Jan; 28(1):76-82. PubMed ID: 16956664
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aggregation of alpha-synuclein by DOPAL, the monoamine oxidase metabolite of dopamine.
    Burke WJ; Kumar VB; Pandey N; Panneton WM; Gan Q; Franko MW; O'Dell M; Li SW; Pan Y; Chung HD; Galvin JE
    Acta Neuropathol; 2008 Feb; 115(2):193-203. PubMed ID: 17965867
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.